{"id":"https://openalex.org/W4310106650","doi":"https://doi.org/10.1182/blood-2022-168491","title":"PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia","display_name":"PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106650","doi":"https://doi.org/10.1182/blood-2022-168491"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-168491","doi":"https://doi.org/10.1182/blood-2022-168491","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-168491","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019249845","display_name":"Daniela Bellarosa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Daniela Bellarosa","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079576888","display_name":"Sonia Zicari","orcid":"https://orcid.org/0000-0003-1240-8057","observed_orcids":["https://orcid.org/0000-0003-1240-8057"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Sonia Zicari","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106085666","display_name":"Giuseppe Merlino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Merlino","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054354563","display_name":"Alessio Fiascarelli","orcid":"https://orcid.org/0000-0002-7453-4262","observed_orcids":["https://orcid.org/0000-0002-7453-4262"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessio Fiascarelli","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053035735","display_name":"Diego Bisignano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Diego Bisignano","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Francesco Belli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesco Belli","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030116404","display_name":"Clelia Irrissuto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Clelia Irrissuto","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074715529","display_name":"Simone Talucci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Simone Talucci","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091151527","display_name":"Maria Luisa Iannitto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Maria Luisa Iannitto","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091013748","display_name":"Mario Bigioni","orcid":"https://orcid.org/0000-0003-1498-5288","observed_orcids":["https://orcid.org/0000-0003-1498-5288"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Mario Bigioni","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019112931","display_name":"Alessandro Bressan","orcid":"https://orcid.org/0000-0002-7922-8440","observed_orcids":["https://orcid.org/0000-0002-7922-8440"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Alessandro Bressan","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025138388","display_name":"Krzysztof D. Brz\u00f3zka","orcid":"https://orcid.org/0000-0001-7563-6482","observed_orcids":["https://orcid.org/0000-0001-7563-6482"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Krzysztof Brz\u00f3zka","raw_affiliation_strings":["2Ryvu Therapeutics, Cracow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Ryvu Therapeutics, Cracow, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069374229","display_name":"Gabriel Ghiaur","orcid":"https://orcid.org/0000-0002-3955-7944","observed_orcids":["https://orcid.org/0000-0002-3955-7944"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210150714","display_name":"Johns Hopkins Hospital","ror":"https://ror.org/05cb1k848","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210150714"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel Ghiaur","raw_affiliation_strings":["3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210150714","https://openalex.org/I4210164401"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085370027","display_name":"Monica Binaschi","orcid":"https://orcid.org/0000-0002-3155-3164","observed_orcids":["https://orcid.org/0000-0002-3155-3164"]},"institutions":[{"id":"https://openalex.org/I4210108499","display_name":"Menarini Group (Italy)","ror":"https://ror.org/02h1wg091","country_code":"IT","type":"company","lineage":["https://openalex.org/I4210108499"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Monica Binaschi","raw_affiliation_strings":["1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (Rome), Italy","institution_ids":["https://openalex.org/I4210108499"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.23824852,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"3090","last_page":"3091"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gilteritinib","display_name":"gilteritinib","score":0.8840000033378601},{"id":"https://openalex.org/keywords/pim-kinase-inhibition","display_name":"PIM kinase inhibition","score":0.8140000104904175},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.9589999914169312},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9929999709129333},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7269999980926514},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6830000281333923},{"id":"https://openalex.org/keywords/flt3-inhibitor-resistance","display_name":"FLT3 inhibitor resistance","score":0.7260000109672546},{"id":"https://openalex.org/keywords/mesenchymal-stem-cells","display_name":"mesenchymal stem cells","score":0.7839999794960022},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7459999918937683},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.45899999141693115},{"id":"https://openalex.org/keywords/pi3k-akt-signaling","display_name":"PI3K/Akt signaling","score":0.6039999723434448},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.6179999709129333},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.5289999842643738},{"id":"https://openalex.org/keywords/combination-index","display_name":"combination index","score":0.3490000069141388},{"id":"https://openalex.org/keywords/mv4-11-cells","display_name":"MV4-11 cells","score":0.6420000195503235},{"id":"https://openalex.org/keywords/molm-13-cells","display_name":"MOLM-13 cells","score":0.9520000219345093}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6098366379737854},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5060405135154724},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.500349760055542},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4890657365322113},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.46348267793655396},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.42501339316368103},{"id":"https://openalex.org/C109159458","wikidata":"https://www.wikidata.org/wiki/Q919283","display_name":"Haematopoiesis","level":3,"score":0.41731369495391846},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3092632293701172},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20468512177467346},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.17776915431022644},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0731254518032074},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-168491","doi":"https://doi.org/10.1182/blood-2022-168491","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-168491","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8199999928474426}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405174604","https://openalex.org/W3178942504","https://openalex.org/W2926816510","https://openalex.org/W2914799005","https://openalex.org/W4389247779","https://openalex.org/W2595683950","https://openalex.org/W2987768032","https://openalex.org/W2989504866","https://openalex.org/W3170232908","https://openalex.org/W4391313605"],"abstract_inverted_index":{"BACKGROUND.":[0],"Acute":[1],"myeloid":[2,18],"leukemia":[3],"(AML)":[4],"is":[5,39,73,148,514,529],"an":[6,12,462],"aggressive":[7],"hematopoietic":[8],"cancer,":[9],"derived":[10],"from":[11,286],"uncontrolled":[13],"clonal":[14],"proliferation":[15],"of":[16,86,115,120,145,157,160,237,319,363,378,404,417,423,437,469,499,503,552,569,585,587,602,605],"malignant":[17],"blast":[19],"cells":[20,322],"in":[21,53,58,100,164,185,202,234,297,314,324,330,428,478,490,517,535,542,617],"the":[22,54,84,113,121,158,173,213,235,317,336,370,389,408,421,438,441,474,494,510,518,583,599],"bone":[23,240],"marrow,":[24],"transformed":[25],"by":[26,582],"recurrent":[27],"genetic":[28],"alterations":[29],"(Wu":[30],"M.":[31,106],"et":[32,68,134],"al.,":[33,69,135],"J.":[34],"Hematol":[35],"Oncol,":[36],"2018).":[37,71],"SEL24/MEN1703":[38,161,194,250,341,373,394,424,449,526],"a":[40,74,325,351,412,429,459,479,564,613],"first-in-class,":[41],"oral,":[42],"type":[43],"I":[44],"dual":[45],"PIM/FMS-like":[46],"tyrosine":[47],"kinase":[48],"3":[49,348,456],"(FLT3)":[50],"inhibitor":[51],"investigated":[52],"ongoing":[55],"Ph2":[56],"study":[57,147],"patients":[59,101],"with":[60,91,102,168,226,448,465,473,525],"AML":[61,90,104,165,187,332],"(DIAMOND-01,":[62],"ClinicalTrials.gov":[63],"identifier:":[64],"NCT03008187)":[65],"(Czardybon":[66],"W.":[67],"Oncotarget":[70],"Gilteritinib":[72,95,116,163,196,252,346,375,390,396,426,454,528],"highly":[75],"potent":[76,566],"and":[77,107,138,155,162,170,179,195,231,246,251,261,301,307,345,361,395,402,425,453,467,505,527,556,571,607],"selective":[78],"oral":[79],"FLT3":[80,92,504,570,576,606],"inhibitor,":[81],"FDA-approved":[82],"for":[83,204,259],"treatment":[85,293,372,447,476,520],"relapsed":[87],"or":[88,201],"refractory":[89],"mutations.":[93],"Although":[94],"showed":[96,400,508],"strong":[97],"single-agent":[98],"activity":[99,354,464],"FLT3+":[103],"(Levis":[105],"Perl":[108],"AE.,":[109],"Blood":[110],"advances,":[111],"2020),":[112],"development":[114],"resistance":[117],"limits":[118],"durability":[119],"response,":[122],"indicating":[123],"that":[124,509],"novel":[125,614],"combination":[126,159,203,207,292,328,371,422,475,519,554],"strategies":[127],"may":[128],"be":[129,561],"clinically":[130],"important":[131],"(Zhang":[132],"LS.":[133],"Onco":[136],"Targets":[137],"Therapy,":[139],"2022).":[140],"AIM.":[141],"The":[142,206,291,549],"main":[143],"objective":[144],"this":[146,491,553],"to":[149,171,212,558,563],"assess":[150],"potential":[151,601],"synergistic":[152,531],"effects":[153],"in-vitro":[154,299],"in-vivo":[156,337,543,555,579],"cell":[166,188,228,333],"lines":[167,189,229],"FLT3-ITD":[169,186,227,544],"elucidate":[172],"underlying":[174],"signaling":[175,266,501,577],"pathways.":[176],"METHODS.In-vitro":[177],"cytotoxicity":[178,300],"apoptosis":[180,302],"experiments":[181,223,303,596],"were":[182,224,253],"carried":[183],"out":[184],"(MV4-11,":[190],"MOLM13,":[191,306],"MOLM14),":[192],"testing":[193],"either":[197],"as":[198,355,397,458,580,592],"single":[199,356,398],"agents":[200,399],"72h.":[205],"index":[208],"was":[209,276,294,392,488],"calculated":[210],"according":[211],"Chou":[214],"method":[215],"(Chou":[216],"TC.,":[217],"Pharmacol":[218],"Rev,":[219],"2006).":[220],"In-vitro":[221],"co-culture":[222,315],"performed":[225,278],"MV4-11":[230,245,338],"MOLM14":[232],"incubated":[233],"presence":[236,318],"human":[238],"primary":[239,320],"marrow":[241],"stromal":[242,321],"cells.":[243],"In":[244,335,440,493],"MOLM13":[247,287,442,495],"xenograft":[248,288,339,496],"models,":[249,545],"administered":[254],"per":[255],"OS":[256],"every":[257],"day,":[258],"14":[260],"22":[262],"days,":[263],"respectively.":[264],"A":[265],"pathway":[267,578],"analysis":[268,498],"(pAKT,":[269],"pERK,":[270],"pSTAT5,":[271],"Mcl-1,":[272],"c-Myc,":[273],"Bcl-xL,":[274],"pS6)":[275],"also":[277],"through":[279],"immuno-capillary":[280],"electrophoresis":[281],"on":[282,304],"tumor":[283,364,414,431,486,537],"nodules":[284],"collected":[285],"study.":[289],"RESULTS.":[290],"moderately":[295,530],"synergistic/additive":[296],"both":[298],"MV4-11,":[305],"MOLM14,":[308],"at":[309,342,347,380,444,450,455,546],"all":[310],"concentration":[311],"levels.":[312],"However,":[313],"experiments,":[316],"resulted":[323,427,477],"significantly":[326],"increased":[327],"index,":[329],"tested":[331],"lines.":[334],"model,":[340,443,497],"25":[343,451],"mg/kg":[344,349,452,457],"induced":[350,376,411,461],"significant":[352],"anti-tumor":[353],"agent":[357],"treatment,":[358],"showing":[359],"57.2%":[360],"84.1%":[362],"volume":[365],"inhibition":[366,568,604],"(TVI)":[367],"respectively,":[368,406,471],"whereas":[369,407,472],"plus":[374],"99.2%":[377],"TVI":[379,405,470,481],"day":[381,386,445],"33":[382],"(Figure":[383],"1).":[384],"At":[385],"40,":[387],"when":[388],"schedule":[391],"concluded,":[393],"53.1%":[401],"87.6%":[403],"combo":[409],"group":[410],"complete":[413,485,540],"regression":[415,487],"(100%":[416],"TVI).":[418],"Moreover,":[419],"only":[420],"delayed":[430],"regrowth":[432],"23.5":[433],"days":[434],"after":[435],"discontinuation":[436],"treatment.":[439],"29,":[446],"monotherapy":[460,559],"antitumor":[463,600],"38.8%":[466],"60.1%":[468],"higher":[480,550],"(78.3%),":[482],"however,":[483,533],"no":[484],"observed":[489],"model.":[492],"downstream":[500,588],"pathways":[502],"PIM":[506,572,608],"kinases":[507,573,609],"pS6":[511],"effector":[512,589],"protein":[513],"mainly":[515],"downregulated":[516],"group.":[521],"CONCLUSIONS.":[522],"Combination":[523],"therapy":[524],"in-vitro,":[532],"results":[534],"robust":[536],"regressions,":[538],"including":[539],"responses":[541],"tolerable":[547],"doses.":[548],"efficacy":[551],"compared":[557],"could":[560,611],"related":[562],"very":[565],"concomitant":[567,603],"affecting":[574],"upregulated":[575],"demonstrated":[581,598],"reduction":[584],"phosphorylation":[586],"proteins,":[590],"such":[591],"pS6.":[593],"Overall,":[594],"these":[595],"have":[597],"which":[610],"drive":[612],"therapeutic":[615],"strategy":[616],"AML.":[618],"Figure":[619],"1View":[620,623],"largeDownload":[621,624],"PPTFigure":[622],"PPT":[625],"Close":[626],"modal":[627]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2022-11-30T00:00:00"}